Business Development

Our clients are faced with hard choices: Where to invest? Where to innovate? Where to focus attention? Who to partner with? How to expand the business? And most importantly, how to get return on investment? Each of these decisions carries with it an amount of uncertainty. Deallus minimises this uncertainty by providing thorough due diligence and then highlighting the relevant insights through deep analysis. Our solutions and recommendations, based on real-world data and analytical modelling, have a proven track record of generating value for our clients.

Partnership Strategies

Issue:

  • Our client, a top-10 bio-pharma company, wanted to evaluate the opportunity to expand their business into Canada. The client requested a financial analysis of the opportunity based on the possibility that a suitable company could be identified for partnership.

Solution:

  • Deallus divided the analysis in three components; firstly analysing the entry strategies of 6 pharma companies, identifying the drivers, their assets and other commercial/financial considerations that were valid at the time of entry. Secondly, we performed a P&L analysis of the putative opportunity to identify areas of particular sensitivity and risk. Finally we undertook a partnership fit analysis by reviewing the capabilities, strengths and weaknesses of relevant companies with an established presence in the market and with recognised commercial synergies with the client’s portfolio. Deallus provided a viable entry strategy based on financial modeling, peer-group benchmarking, case-study, and goals vs. capabilities analysis. Using this, the client was able to fund a strategy to reach their strategic endpoints.

Issue:

  • Our client, a top-10 biotechnology company, requested a recommendation on how to partner with stakeholders in diagnostics development in order to maximise the economic value added in drug-diagnostic co-development across their drug programs.

Solution:

  • In order to achieve this, Deallus conducted due diligence on the business models of a variety of stakeholders in the diagnostics industry, and stakeholder core competencies were overlaid with the economic goals of the client’s drug programs. This allowed them to advance partnering discussions based on Deallus recommendations for specific drug development assets.

New Area Scoping

Issue:

  • Our client required a commercial evaluation to inform the clinical development strategy of an early (Phase Ib) oncology drug in order to select appropriate indications to pursue for the Phase II clinical program.

Solution:

  • Deallus performed a 360 degree analysis of the commercial opportunities for the asset by evaluating 20 oncology indications. Through this process we were able to recommend 4 specific cancer indications that offered a balanced combination of risk and upside in line with the client’s own risk appetite for this particular asset.

Merger/Acquisition & Licensing

Issue:

  • Our client wanted to determine quickly the attractiveness of an antibacterial asset for possible in-licensing in the APAC region, at the expense of divesting a similar asset in their existing portfolio. The consequence of this decision would directly impact the economic value of our client’s drug pipeline and future portfolio. The client was set to make a decision in 2 weeks and so a fast turnaround was essential.

Solution:

  • Utilizing multi-source insights, Deallus was able to provide an objective, third-party analysis of the antibacterial asset, focusing on the clinical development programme, drug safety profile, and projected NDA submission timelines. This culminated in our recommendation to the client as to the suitability and strategic fit of the asset as an acquisition target.